Neuberger Berman Group
MDGL icon

Neuberger Berman Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Neuberger Berman Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$441K Sell
822
-12,027
-94% -$6.16M ﹤0.01% 1853
2026
Q1 		$6.73M Sell
12,849
-5,811
-31% -$2.78M 0.01% 922
2025
Q4 		$10.9M Buy
18,660
+129
+0.7% +$65.9K 0.01% 787
2025
Q3 		$8.5M Buy
+18,531
New +$6.91M 0.01% 840
2025
Q2 		– Sell
-692
Closed -$229K – 2099
2025
Q1 		$229K Sell
692
-21,436
-97% -$7.04M ﹤0.01% 1785
2024
Q4 		$6.83M Buy
+22,128
New +$6.22M 0.01% 885
2023
Q4 		– Sell
-6,817
Closed -$996K – 1897
2023
Q3 		$996K Buy
+6,817
New +$1.28M ﹤0.01% 1257
2013
Q4 		– Sell
-1,126
Closed -$249K – 1642
2013
Q3 		$249K Sell
1,126
-43
-4% -$9.15K ﹤0.01% 1458
2013
Q2 		$204K Buy
+1,169
New +$305K ﹤0.01% 1491

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neuberger Berman Group's MDGL Position: Q2 2026 in Review

Neuberger Berman Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 94% in Q2 2026, selling an estimated $6.16M and leaving 822 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #1853.

Neuberger Berman Group first reported a position in MDGL in Q2 2013 and has held it in 9 quarters since. The position peaked at $10.9M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Neuberger Berman Group held 822 shares of Madrigal Pharmaceuticals worth $441K as of Q2 2026.
  • Neuberger Berman Group sold 12,027 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.16M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1853 holding.
  • Neuberger Berman Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
  • Neuberger Berman Group's Madrigal Pharmaceuticals position peaked at $10.9M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.